Pharmaceuticals & Life Sciences Articles & Blogs

Court of Appeal rules on how to calculate damages in liability clause

Thursday, 12 December 2024

Clarifying liability caps: Key lessons from the Topalsson v Rolls Royce case

Court of Appeal rules on how to calculate damages in liability clause

Research and development subsidies - report into the £129 million grant funding to BioNTech for the life sciences sector

Monday, 02 December 2024

This blog examines the Subsidy Advice Unit (SAU) report into a proposed subsidy by the Department of Science Innovation and Technology (DSIT) to BioNTech UK Limited (BioNTech).

Research and development subsidies - report into the £129 million grant funding to BioNTech for the life sciences sector

Articles & Blogs Pharma & Life Sciences

Life Sciences and sustainability shine in new UK industrial strategy

Tuesday, 19 November 2024

"Growth is the number one mission of this government. Our new Industrial Strategy is central to that Growth Mission". So starts the Green Paper setting out the new UK Government's vision for an Industrial Strategy that plans to 2035 and beyond.

Life Sciences and sustainability shine in new UK industrial strategy

Articles & Blogs Pharma & Life Sciences

Protecting data: implications of the Cyber Security and Resilience Bill for the UK's pharmaceuticals and life sciences sector

Tuesday, 19 November 2024

The proposed Cyber Security and Resilience Bill (the Bill) intends to capture more sectors, increase incident reporting and strengthen ICO powers - we consider the potential implications for the UK's pharmaceuticals and Life Sciences sector.

Protecting data: implications of the Cyber Security and Resilience Bill for the UK's pharmaceuticals and life sciences sector

Articles & Blogs Pharma & Life Sciences

AI and copyright - moving closer to a solution?

Tuesday, 19 November 2024

Lawmakers are addressing how to govern the use of copyrighted materials for training AI models. This article examines the situation in the UK and Europe.

AI and copyright - moving closer to a solution?

Articles & Blogs Pharma & Life Sciences

Poorly drafted no assignment clause did not stop novation by conduct

Friday, 18 October 2024

A contractual clause prohibiting assignment without the other party's prior written consent did not stop the novation (ie replacement) of one of the parties by another party, the High Court has ruled.

Poorly drafted no assignment clause did not stop novation by conduct

Articles & Blogs Pharma & Life Sciences

MANIFEST: The Francis Crick Institute launches a new project aimed at understanding immunotherapy responses and side effects in cancer treatments

Friday, 18 October 2024

This month has seen the launch of a £9 million partnership led by The Francis Crick Institute which aims to understand patient responses to immunotherapy, enabling the development of safer and more effective treatments.

MANIFEST: The Francis Crick Institute launches a new project aimed at understanding immunotherapy responses and side effects in cancer treatments

Articles & Blogs Pharma & Life Sciences

MedCity unveils thriving future for life sciences in London

Wednesday, 09 October 2024

MedCity has revealed an exciting vision for London as the premier global destination for life science - that brings together world leading research, an exceptional health system, a thriving commercial ecosystem and first class talent.

Articles & Blogs Pharma & Life Sciences

Did adjective apply to the whole list or just the first item? Court of Appeal gives ruling

Wednesday, 25 September 2024

Sometimes, parties to contracts look back at the wording they used and wish they would have been clearer.

Did adjective apply to the whole list or just the first item? Court of Appeal gives ruling

Articles & Blogs Pharma & Life Sciences

Digital dose: using social media and online platforms to market and sell medicines and medical products

Wednesday, 25 September 2024

Recent attention has focused on the relationship between social media and medical products, as healthcare professionals noted an increase in influencers marketing unlicensed versions of the weight loss drug, semaglutide (branded as Ozempic and Wegovy).

Digital dose: using social media and online platforms to market and sell medicines and medical products

Articles & Blogs Pharma & Life Sciences

Key Deadlines for the Windsor Framework: what you need to know about medicine regulations

Wednesday, 25 September 2024

Marketing authorisation holders (MAHs) are required to take specific actions regarding their product licenses in Northern Ireland (NI) and Great Britain (GB) by 30 September 2024 to avoid potential regulatory complications.

Key Deadlines for the Windsor Framework: what you need to know about medicine regulations by 1 Jan 2025 (and 30 September 2024)

Articles & Blogs Pharma & Life Sciences

How's it going for pharma SMEs in the EU?

Wednesday, 04 September 2024

In the EU, there are regulations - lots of them. There's even a specific regulation for micro, small and medium-sized enterprises (SMEs) in the pharma sector. The EU is seeking opinions on support for pharmaceutical SMEs.

How's it going for pharma SMEs in the EU?

Articles & Blogs Pharma & Life Sciences

£100 million boost to quantum hubs to aid life sciences innovations

Wednesday, 04 September 2024

The UK Government has recently allocated substantial funding of over £100 million to support five new quantum research hubs across the UK.

£100 million boost to quantum hubs to aid life sciences innovations

Articles & Blogs Pharma & Life Sciences

Long term agreements still apply even when things change

Tuesday, 03 September 2024

When a licensee entered into a trade mark licence for 25 years and decided five years in that they did not want to use the trade mark any more, they were still required to pay the large minimum royalties, the Court of Appeal has ruled.

Long term agreements still apply even when things change

Articles & Blogs Pharma & Life Sciences

PING 2024 round-up - 'AI in pharma - Threat or opportunity?'

Tuesday, 16 July 2024

Over a month has passed since the 2024 PING conference, providing invaluable insights into the uptake of AI in Pharma, its transformational promise, and the accompanying risks and pitfalls. Below is a summary of our key takeaways.

PING 2024 round-up - 'AI in pharma - Threat or opportunity?'

Pharma & Life Sciences

Share this page: